Udvalget konstaterede, at dokumentationen for virkningerne af Yondelis hovedsagelig bygger på behandling af liposarkom og leiomyosarkom.
The Committee noted that evidence of Yondelis’ s effects is mainly based on the treatment of liposarcoma and leiomyosarcoma.